International audienceBackground: Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. The constitutive expression of HIF-1α in MM suggests that inhibition of HIF-1α-mediated transcription represents an interesting target in MM.Methods: As p300 is a crucial co-activator of hypoxia-inducible transcription, disrupting the complex HIF-1α/p300 to target HIF activity appears to be an attractive strategy.Results: We reported that chetomin, an inhibitor of HIF-1α/p300 interaction, exhibits antitumour activity in human myeloma cell lines and primary MM cells from patients.Conclusions: Our data suggest that chetomin may be of clinical value in MM and especially for patients characterised by a high EP300/HIF-1α expression and a poor p...
UnlabelledMultiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although t...
International audienceBACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel c...
Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%)...
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by accumulation of malignant plasm...
none14noThe increasing importance of hypoxia-inducible factor-1α (HIF-1α) in tumorigenesis raises th...
Despite recent advancements in therapy, multiple myeloma (MM) remains incurable. While the reasons f...
AbstractHomeostasis under hypoxic conditions is maintained through a coordinated transcriptional res...
none12noMultiple myeloma (MM) is a malignant disorder of post-germinal center B cells, characterized...
This thesis is focused on multiple myeloma (MM), a haematological malignancy that still remains incu...
Multiple myeloma (MM) is a blood cancer characterised by the uncontrolled proliferation and dissemin...
Developing effective therapies against multiple myeloma (MM) is an unresolved challenge. Phosphatidy...
International audienceBACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease with a po...
The oncogenic transcription factor STAT3 is aberrantly activated in over 70% of human tumours, inclu...
Purpose: To investigate the role of hypoxia-inducible factor-1a (HIF-1a) in angiogenesis and drug re...
Multiple myeloma (MM) is an incurable disease of malignant plasma B-cells that infiltrate the bone m...
UnlabelledMultiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although t...
International audienceBACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel c...
Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%)...
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by accumulation of malignant plasm...
none14noThe increasing importance of hypoxia-inducible factor-1α (HIF-1α) in tumorigenesis raises th...
Despite recent advancements in therapy, multiple myeloma (MM) remains incurable. While the reasons f...
AbstractHomeostasis under hypoxic conditions is maintained through a coordinated transcriptional res...
none12noMultiple myeloma (MM) is a malignant disorder of post-germinal center B cells, characterized...
This thesis is focused on multiple myeloma (MM), a haematological malignancy that still remains incu...
Multiple myeloma (MM) is a blood cancer characterised by the uncontrolled proliferation and dissemin...
Developing effective therapies against multiple myeloma (MM) is an unresolved challenge. Phosphatidy...
International audienceBACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease with a po...
The oncogenic transcription factor STAT3 is aberrantly activated in over 70% of human tumours, inclu...
Purpose: To investigate the role of hypoxia-inducible factor-1a (HIF-1a) in angiogenesis and drug re...
Multiple myeloma (MM) is an incurable disease of malignant plasma B-cells that infiltrate the bone m...
UnlabelledMultiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although t...
International audienceBACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel c...
Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%)...